Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT ...

Monash researchers have studied what happens in the brain when it is being treated with Transcranial Direct Current Stimulation (tDCS), a non-invasive brain stimulation technique in which ...

The global interferons market is on a remarkable growth trajectory, with a projected valuation of USD 13.8 billion by 2032, ...

Brain stimulation using electrodes placed on the head has a great potential to be used in clinical practice to treat ...

Brain stimulation using electrodes placed on the head has a great potential to be used in clinical practice to treat depression, anxiety and even ...

A comprehensive analysis of neuromodulatory inputs to insulin-producing cells in fruit flies shows how individual cell responses are integrated to allow animals to rapidly respond to changing ...

Using a combination of single-nucleus transcriptome analyses, anatomical receptor mapping, optogenetics, whole cell patch-clamp recordings, calcium imaging, and connectomics, we unravel how individual ...

Lund, Sweden and Strasbourg, France, September 9, 2024, 07:00 am CEST- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of ...

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with ...

BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients.Promising efficacy data in combination with KEYTRUDA® (pembrolizumab) with partial responses in ...

Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) have been observed in the single agent part of the Phase 2a study. Three ...

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV)Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (C ...